Nanotechnology Now

Our NanoNews Digest Sponsors


Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > Nanoparticles Assembled Inside Tumors Trap Drugs and Imaging Agents

Abstract:
Virtually every study that uses nanoparticles to deliver drugs and imaging agents to tumors starts by loading the clinical payload into the nanoparticle and then injecting the resulting delivery agent into the body.

Nanoparticles Assembled Inside Tumors Trap Drugs and Imaging Agents

Bethesda, MD | Posted on July 19th, 2010

While effective at reducing clearance from the body and improving drug or imaging agent retention in a tumor, the nanoparticles do move relatively slowly from the circulation into the heart of the tumor.

Now, a pair of investigators from the University of Toronto have shown that a system that assembles itself into a nanoparticle, complete with drug or imaging agent, once it gets inside a tumor can dramatically increase the rate at which clinically important molecules get into tumors and still trap those molecules inside the tumor. Warren Chan and postdoctoral fellow Steven Perrault conducted the study and published the results of their work in the Proceedings of the National Academy of Sciences.

The goal of this project was to develop a nanoparticle system that would combine the fast "in" rate for small molecule drugs or imaging agents with the glacial "out" rate associated with nanoparticles. This would allow as much drug or imaging agent to get into and stay in tumors while allowing the body to excrete rapidly any of the active material that remained in the blood stream or that happened to get inside of non-targeted tissue. To create a system that would marry these two seemingly incompatible characteristics, Drs. Chan and Perrault first inject 30 nanometer diameter gold nanoparticles coated with a biotin terminated polymer; the polmer keeps the particles from sticking to one another and the biotin allows for later conjugation to imaging agents or drugs. Over the course of the next 24 hours, many of the gold nanoparticles accumulate in tumors, while the rest are excreted from the body.

Next, the researchers inject the active substance linked to streptavidin, a molecule that binds tightly and specifically to biotin. This small molecule construct readily enters tumors, as well as other tissues, but once in the tumors it sticks in an almost irreversible manner to the gold nanoparticles, greatly reducing the rate at which the active molecule will exit the tumor.

Using a fluorescent dye as the active molecule linked to streptavidin, Drs. Chan and Perrault were able to track the kinetics of drug accumulation in tumor. The results were remarkable: the active molecule accumulated nearly 200-fold increase in the rate at which drug accumulated in tumors compared to animals that did not receive the biotin-coated gold nanoparticles. In addition, pretreated tumors accumulated five times more of the fluorescent probe than did the control animals.

This work is detailed in a paper titled, "In vivo assembly of nanoparticle components to improve targeted cancer imaging." An abstract of this paper is available at the journal's Web site.

View abstract dx.doi.org/doi:10.1073/pnas.1001367107

####

About NCI Alliance for Nanotechnology in Cancer
To help meet the goal of reducing the burden of cancer, the National Cancer Institute (NCI), part of the National Institutes of Health, is engaged in efforts to harness the power of nanotechnology to radically change the way we diagnose, treat and prevent cancer.

The NCI Alliance for Nanotechnology in Cancer is a comprehensive, systematized initiative encompassing the public and private sectors, designed to accelerate the application of the best capabilities of nanotechnology to cancer.

Currently, scientists are limited in their ability to turn promising molecular discoveries into benefits for cancer patients. Nanotechnology can provide the technical power and tools that will enable those developing new diagnostics, therapeutics, and preventives to keep pace with today’s explosion in knowledge.

For more information, please click here

Copyright © NCI Alliance for Nanotechnology in Cancer

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Cooling graphene-based film close to pilot-scale production April 30th, 2016

Personal cooling units on the horizon April 29th, 2016

Exploring phosphorene, a promising new material April 29th, 2016

The Translational Research Center at the University Hospital of Erlangen in Germany uses the ZetaView from Particle Metrix to quantify extracellular vesicles such as exosomes April 28th, 2016

Possible Futures

Cooling graphene-based film close to pilot-scale production April 30th, 2016

Personal cooling units on the horizon April 29th, 2016

Exploring phosphorene, a promising new material April 29th, 2016

Hybrid nanoantennas -- next-generation platform for ultradense data recording April 28th, 2016

Academic/Education

JPK reports on the use of a NanoWizard AFM system at the University of Kaiserslautern to study the interaction of bacteria with microstructured surfaces April 28th, 2016

The Ottawa Hospital Research Institute uses the ZetaView from Particle Metrix to study membrane microparticles as potential biomarkers for underlying diseases April 12th, 2016

FEI Partners with Five Pharmaceutical Companies, the Medical Research Council and the University of Cambridge to form Cryo-EM Research Consortium April 5th, 2016

SUNY Poly, in Collaboration with the George Washington School of Medicine and Health Sciences and Stony Brook University, Demonstrates Pioneering Method to Visualize and Identify Engineered Nanoparticles in Tissue March 25th, 2016

Nanomedicine

Nanoparticles hold promise as double-edged sword against genital herpes April 28th, 2016

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1/2 Study of ARC-521 April 28th, 2016

The Translational Research Center at the University Hospital of Erlangen in Germany uses the ZetaView from Particle Metrix to quantify extracellular vesicles such as exosomes April 28th, 2016

JPK reports on the use of a NanoWizard AFM system at the University of Kaiserslautern to study the interaction of bacteria with microstructured surfaces April 28th, 2016

Announcements

Cooling graphene-based film close to pilot-scale production April 30th, 2016

Personal cooling units on the horizon April 29th, 2016

Exploring phosphorene, a promising new material April 29th, 2016

The Translational Research Center at the University Hospital of Erlangen in Germany uses the ZetaView from Particle Metrix to quantify extracellular vesicles such as exosomes April 28th, 2016

Nanobiotechnology

Nanoparticles hold promise as double-edged sword against genital herpes April 28th, 2016

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1/2 Study of ARC-521 April 28th, 2016

The Translational Research Center at the University Hospital of Erlangen in Germany uses the ZetaView from Particle Metrix to quantify extracellular vesicles such as exosomes April 28th, 2016

JPK reports on the use of a NanoWizard AFM system at the University of Kaiserslautern to study the interaction of bacteria with microstructured surfaces April 28th, 2016

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







Car Brands
Buy website traffic